1070892-04-4

Usage

Uses

Used in Pharmaceutical Industry:
5-bromo-2-(trifluoromethyl)isonicotonitrile is used as a synthetic intermediate for the development of new drugs and agrochemicals, leveraging its chemical properties to create novel therapeutic agents.
Used in Drug Metabolism Studies:
As a potent inhibitor of the cytochrome P450 enzyme, 5-bromo-2-(trifluoromethyl)isonicotonitrile is utilized in research to understand and modulate drug metabolism processes, which is vital for assessing drug efficacy and safety.
Used in Antimicrobial and Antifungal Applications:
5-bromo-2-(trifluoromethyl)isonicotonitrile is employed for its antimicrobial and antifungal activity, making it a valuable component in the development of treatments for infectious diseases.
Used in Organic Synthesis:
5-bromo-2-(trifluoromethyl)isonicotinonitrile serves as a building block in the synthesis of other organic compounds, contributing to the advancement of chemical research and the creation of new materials with diverse applications.

Upstream product

• 1070972-53-0 C₇H₂BrClF₃NO 
• 749875-16-9 5-bromo-2-(trifluoromethyl)pyridine-4-carboxylic acid 
• 436799-32-5 5-bromo-2(trifluoromethyl)pyridine 
• 1070892-03-3 5-bromo-2-trifluoromethylisonicotinamide 

Downstream Products

• 1070973-30-6 4-chloro-5-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-2-methoxy-benzenesulfonyl chloride 
• 1070973-28-2 4-chloro-5-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-2-methoxy-N-methyl-N-phenyl-benzenesulfonamide 
• 1070973-61-3 4-chloro-5-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-2-hydroxy-N-methyl-N-phenyl-benzenesulfonamide 
• 1070973-59-9 [5-chloro-4-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-2-(methyl-phenyl-sulfamoyl)-phenoxy]-acetic acid 
• 1070973-60-2 [5-chloro-4-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-2-(methyl-phenyl-sulfamoyl)-phenoxy]-acetic acid tert-butyl ester 
• 1070973-41-9 4-[5-chloro-4-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-2-(methyl-pyridin-2-yl-sulfamoyl)-phenoxy]-butyric acid 
• 1070973-20-4 4-[5-chloro-4-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-2-(4,4-dimethyl-3,4-dihydro-2H-quinoline-1-sulfonyl)-phenoxy]-butyric acid 
• 1070973-07-7 4-[5-chloro-4-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-2-(2,3,4,5-tetrahydro-benzo[b]azepine-1-sulfonyl)-phenoxy]-butyric acid 
• 1070890-41-3 4-[5-chloro-4-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-2-(methyl-o-tolyl-carbamoyl)-phenoxy]-butyric acid 
• 1070892-94-2 4-chloro-5-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-N-(2,6-dimethyl-phenyl)-2-methoxy-benzamide 
• 1070891-28-9 4-chloro-5-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-N-(2,6-dimethyl-phenyl)-2-methoxy-N-methyl-benzamide 
• 1070892-93-1 4-chloro-2-methoxy-5-(6-trifluoromethyl-pyridin-3-yl)-benzoyl chloride 
• 1070892-92-0 4-chloro-5-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-2-methoxy-benzoic acid 
• 1070892-55-5 4-[5-chloro-4-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-2-(methyl-o-tolyl-carbamoyl)-phenoxy]-butyric acid tert-butyl ester 

Relevant academic research and scientific papers

IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF

The present disclosure provides compounds represented by Formula (I) wherein R1, R2, R3, and R4 are as defined in the specification, and the salts and solvates thereof. Compounds of Formula (I) are FED inhibitors. FED inhibitors are useful for the treatment of cancer and other diseases.

GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure, wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.